Skip Navigation

Evidence-Based Toxicology Collaboration

Board of Trustees

EBTC Board of Trustees

John “Jack” R. Fowle III PhD, DABT
EBTC Board President

Dr. John R. “Jack” Fowle III is the principal of Science to Inform, LLC, an independent consultant advising clients about the use of science to inform decisions regarding environmental risk and in the development and use of alternatives for animal testing.

Prior to 2012 he was the Deputy Director of the U.S. Environmental Protection Agency’s (EPA) Health Effects Division in the Office of Pesticide Programs (OPP) in Washington, DC and was responsible for directing the health risk assessment activities supporting the re-registration of existing pesticides. Dr Fowle managed the integration of new toxicological approaches into OPP’s human health risk assessments.  Before OPP, he was Director of EPA’s Neurotoxicology Division, as well as Assistant Laboratory Director, at the National Health and Environmental Effects Research Lab (NHEERL) in Research Triangle Park, NC helping to develop alternatives to animal approaches and to establish the Agency’s computational toxicology program. Dr Fowle has served as Deputy Director of EPA’s Science Advisory Board and as the Science Advisor to U.S. Senator Daniel Patrick Moynihan.

Since retiring from EPA Dr Fowle serves on the Board of Directors for the Institute of In Vitro Sciences in Gaithersburg, MD, is President of the Board of Trustees for the Evidence Based Toxicology Consortium and is an AltTox Editor.  He is Councilor for the American Society for Cellular and Computational Toxicology as well as President of the Society of Toxicology’s In Vitro and Alternative Methods Specialty section. Dr Fowle received his baccalaureate and doctoral degrees in genetics from George Washington University in Washington, D.C. and he is a board certified toxicologist.

Rob de Vries, PhD
EBTC Board Vice-President
Chair 
ad interim of the Scientific Advisory Council

Dr de Vries studied biology and philosophy and has a PhD in the ethics of animal experimentation. His research has always focused on the intersection between ethics and methodological aspects of animal experiments. He currently works as a scientific researcher and coordinator at SYRCLE (the SYstematic Review Centre for Laboratory animal Experimentation) in Nijmegen, the Netherlands. Dr de Vries is mainly responsible for organizing hands-on training in systematic reviews of animal studies and for coaching researchers who are conducting their own systematic reviews. He has been involved in several systematic reviews related to food safety, environmental safety, and harmful effects of medical interventions.

James J. Freeman, PhD, DABT
EBTC Board Secretary

Dr Feeman has a PhD in toxicology and is currently the lead toxicology contact to the ExxonMobil basestocks/specialties/asphalt business functions. He is also the technical secretary to the ExxonMobil Occupational Exposure Limit committee and the toxicology staff representative to ExxonMobil’s Health Research Ethics Committee. Dr Freeman began his career in Toxicology in the mid-1970s as a laboratory technician, and joined ExxonMobil in 1985 after receiving his PhD. He has held numerous positions, including Laboratory Director and other management positions in Toxicology and Product Stewardship. Dr Feeman has published on ExxonMobil and industry research activities related to the skin carcinogenicity of petroleum streams, the safety of medicinal- and food-grade mineral hydrocarbons, and the application of the Global Harmonized System to petroleum hydrocarbons. He has served on expert science advisory panels in the US for the Environmental Protection Agency and the Interagency Coordinating Committee for Validation of Alternative Methods (ICCVAM), efforts related to validation of toxicity test methods by the Organization for Economic Coordination and Development (OECD), as an invited industry observer to the International Agency for Research on Cancer (IARC), and as Chairperson to the NTP Scientific Advisory Committee on Alternative Test Methods (SACATM). Jim is currently Chairperson of the external advisory board to the Center for Alternatives to Animal Testing (CAAT) and a member of the Board of Directors to the Evidence-based Toxicology Collaboration. Jim is also a past-president and treasurer of the Mid-Atlantic Chapter, Society of Toxicology.

Thomas Hartung, MD, PhD
EBTC Board Treasurer

Dr Hartung is the Director of the Center of Alternatives to Animal testing at Johns Hopkins University. Professor Hartung’s career is focused on the paradigm shift in toxicity testing for improving public health. In his previous role as head of the European Centre for the Validation of Alternative Methods of the European Commission (2002-2008), and his current leadership of the Johns Hopkins Center for Alternatives to Animal Testing (CAAT), he was involved in the implementation of the 2007 NRC vision document Toxicity Testing in the 21st Century: A Vision and a Strategy. Dr Hartung pioneered the concept of evidence-based toxicology and co-founded the EBTC in 2011 to further its implementation. Dr. Hartung has a broad background in clinical and experimental pharmacology and toxicology, and has authored more than 450 publications. His previous work centered on the immune recognition of bacteria, including pyrogen testing and the induced inflammatory responses, as well as the pharmacological modulation of these responses. In addition to being Director of CAAT, Dr Hartung has established a laboratory for developmental neurotoxicity research based on genomics and metabolomics, with the respective technologies made available by a “Thought Leader” award from Agilent Technologies.

Nancy Beck, PhD, DABT

Dr. Beck is a toxicologist with fifteen years of applied public health experience. She brings to EBTC a broad policy perspective, deep understanding of US regulatory process, as well as detailed technical expertise and an ability to bring a scientific dialogue to the policy discussion to inform critical decision making. Dr. Beck is skilled in leading and directing interagency negotiations to improve policy, as well as establishing successful collaborations and partnerships with senior staff and policy officials throughout the Executive Office of the President and federal agencies.

Gerry Kenna, PhD

Dr. Kenna is Pharmaceutical Director of the Safer Medicines Trust, which is an independent UK charity.  In this role, he is focused on developing and gaining regulatory acceptance of human biology-based methods that can improve human safety assessment of drugs and other chemicals.  In addition, he is an independent Drug Safety Consultant who advises clients in pharmaceutical and biotech companies on how best to select and develop efficacious and safe new drugs, and to validate new predictive safety methods and strategies.  Previously, he held scientific leadership roles as a toxicologist in the pharmaceutical and agrochemical industries (at AstraZeneca, Syngenta and Zeneca).  These were preceded by academic faculty positions (at Imperial College School of Medicine, London UK; National Institutes of Health, MD USA; King’s College Hospital Medical School, London UK and the National Institute for Medical Research, London UK), in which he led research teams that explored mechanisms underlying human adverse drug reactions.  He has authored or co-authored >100 peer reviewed scientific publications, is a member of the International Society for the Study of Xenobiotics and a Fellow of the British Toxicology Society. He received a BSc Hons in Biochemistry from the University of Leeds UK and a PhD in Biochemistry from the University of London UK.

 

Andrew A. Rooney, PhD

Dr Rooney is the Deputy Director, Office of Health Assessment and Translation (OHAT) in the Division at the National Toxicology Program (NTP), National Institute of Environmental Health Sciences (NIEHS). He has 20 years of experience in toxicology and risk assessment for the protection of public health resulting in contributions to the peer-reviewed literature, government assessments (NTP Monographs, EPA IRIS Toxicological Reviews), and book chapters. He has been actively involved in developing risk assessment methods and guidance throughout his professional career, and is a principal author of the 2012 WHO/IPCS Guidance for Immunotoxicity Risk Assessment for Chemicals. Most recently, Dr Rooney has been working on emerging issues in toxicology and environmental health, including methods to address study quality in terms of risk of bias for human, animal, and mechanistic studies, and adaptation of systematic review methods for addressing environmental health questions. He led the team that developed the OHAT Approach to Systematic Review and Evidence Integration. Dr. Rooney has an MS and PhD in zoology from the University of Florida.

Emily S Sena, PhD

Dr Sena is a Research Fellow at the Centre for Clinical Brain Sciences, University of Edinburgh, Convener, CAMARADES. She has a background in neuroscience and is a research fellow specialised in the validity of preclinical studies. Her research interests are in the use of systematic review and meta-analysis of preclinical efficacy studies to increase the understanding of critical facets of translational medicine and developing new hypotheses for testing in the laboratory. Since 2015 Dr Sena has led the Collaborative Approach to Meta-Analysis and Review of Animal Data from Experimental Studies (CAMARADES), a multicentre international research collaboration facilitating the pooling and analysis of data from a range of disease models across the basic sciences. To support this she has developed an internationally accessible database, similar to the Cochrane library, to facilitate interpretation of the preclinical data used to justify progression to clinical trial. Dr Sena's research has informed laboratory practice guidelines, editorial policy and the design of clinical trial protocols.

Didier Verloo, PhD

Didier Verloo is working for the European Food Safety Authority (EFSA) since 2005 where he is heading the Assessment and Methodological Support Unit since 2008. This multidisciplinary unit leads and supports the development, implementation and review of evidence based risk assessment and decision support approaches in all fields within EFSA’s remit and was responsible for the EFSA guidance on Systematic Review in food and feed safety risk assessment and the EFSA guidance on Expert Knowledge Elicitations. Recently the unit developed and started to implement an overall framework for Promoting Methods for Evidence Use in Scientific assessments (Prometheus).

Didier Verloo graduated as a Veterinarian in 1995 and started his professional career at the Institute of Tropical Medicine in Antwerp on the development of diagnostics, interpretation and medical decision making based on diagnostic test results in human and animal trypanosomosis (sleeping sickness) and worked from 2000-2005 for the Belgian government as an epidemiologist and Risk Assessor. Over those years he built up academic and hands on experience in biostatistics, epidemiology, risk analysis, test validation and provided risk analysis consultancy in public health, construction, finance and engineering.  

The EBTC staff members Drs. Katya Tsaioun, Martin L. Stephens, and Sebastian Hoffmann are non-voting members of the Board of Trustees.